REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ashvattha Therapeutics, a clinical-stage biotech company focused on the development of novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular and inflammatory diseases, today announced that Jeffrey Cleland, Ph.D., Chairman, CEO & President, is scheduled to attend and present corporate updates at the following investor conferences:
- 10th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 23 – Private Company Exhibition 1x1 Meetings
- H.C. Wainwright Global Life Sciences Conference on Friday, March 5 at 4:00 PM ET. Prerecorded presentation available starting on Tuesday, March 9 at 7:30 a.m. ET (4:30 a.m. PT)
“We are excited to present at these upcoming conferences and give investors an update on our pipeline. We have made extensive progress on our lead program, OP-101, with Phase 2 in severe COVID-19 patients completing enrollment. Our second program, D-4517, for subcutaneous treatment of wet AMD is progressing through IND enabling studies, and demonstration of imaging for brain tumors and brain metastases along with a robust preclinical oncology pipeline,” said Jeffrey Cleland, Ph.D., Chairman, CEO & President, Ashvattha Therapeutics.
The webcasts will be accessible in the News section of the Ashvattha Therapeutics website at https://avttx.com.
About Ashvattha Therapeutics
Ashvattha Therapeutics, a clinical-stage biopharmaceutical company, is developing novel therapeutics that target and alter specific cells in areas of diseased tissues. The Company’s targeted platform technology, hydroxyl dendrimers (HD), is exclusively licensed from Johns Hopkins University. HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs). Ashvattha has initiated multiple programs with HDTs focused on oncology, age-related macular degeneration (AMD), hyperinflammation in diseases such as COVID-19 and neuroinflammatory diseases such as ALS and Alzheimer’s disease. For more information, visit: www.avttx.com.